MiR-34c oligonucleotide enhances chemosensitivity of Ishikawa cell to cisplatin by inducing apoptosis
Related Experiment Video
Updated: May 14, 2026
Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Ling Jiang1, Wei Meng, Jun Zeng
1Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Abstract:
Expression of miR-34c is significantly reduced in human endometrial cancer cells and miR-34c regulates multiple genes associated with cancer cell proliferation, apoptosis and invasiveness. Thus, miR-34c can theoretically become a target that enhances chemotherapy. Upregulation of miR-34c to enhance the chemotherapeutic effect of cisplatin (DDP) has not been studied in human endometrial cancer cells before. In an in vitro study, the human endometrial cancer cell line, Ishikawa, was treated with DDP and miR-34c mimics, alone or in combination. IC50 values were dramatically decreased in cells treated with miR-34c mimics when combined with DDP, to a greater extent than those treated with DDP alone. Furthermore, miR-34c mimics significantly enhanced apoptosis in Ishikawa cells by inhibiting IL-6R expression. Therefore, a combination of miR-34c mimics and DDP could be an effective therapeutic strategy for controlling Ishikawa cell proliferation.
Insights
This study shows that increasing miR-34c levels enhances chemotherapy effectiveness in human endometrial cancer cells. Combining miR-34c mimics with cisplatin (DDP) significantly reduced cancer cell proliferation and increased apoptosis.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- MicroRNA-34c (miR-34c) expression is decreased in endometrial cancer.
- miR-34c influences genes regulating cancer cell proliferation, apoptosis, and invasiveness.
- Targeting miR-34c could potentially enhance chemotherapy efficacy.
Purpose of the Study:
- To investigate the effect of upregulating miR-34c on cisplatin (DDP) chemotherapy in human endometrial cancer cells.
- To evaluate the combination therapy of miR-34c mimics and DDP in vitro.
Main Methods:
- The human endometrial cancer cell line Ishikawa was used for in vitro experiments.
- Cells were treated with DDP, miR-34c mimics, or a combination of both.
- Cell viability (IC50) and apoptosis were assessed.
Main Results:
- Combination therapy significantly reduced IC50 values compared to DDP alone.
- miR-34c mimics enhanced DDP-induced apoptosis in Ishikawa cells.
- miR-34c mimics inhibited Interleukin-6 Receptor (IL-6R) expression, contributing to apoptosis.
Conclusions:
- Upregulating miR-34c in combination with DDP is a promising therapeutic strategy for endometrial cancer.
- This combination therapy effectively controls cancer cell proliferation and enhances apoptosis.
- Targeting miR-34c offers a novel approach to improve DDP chemotherapy outcomes.
